Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Document › Details

Newton Biocapital. (9/29/22). "Press Release: Philippe De Backer Joins Newton Biocapital as a Senior Partner". Brussels.

Region Region Belgium
Organisations Organisation Newton Biocapital S.A. (NBC)
  Group Newton Biocapital (NBC) (Group)
  Organisation 2 Belgium (govt)
Products Product venture capital
Persons Person De Backer, Philippe (Newton Biocapital 202209– Senior Partner formerly Belgian Minister + Secretary of State)
  Person 2 Parthoens, Alain (Newton Biocapital 201810 Managing Director before Vesalius Biocapital)

Newton Biocapital (NBC), a venture capital firm focused on investing and growing early-stage life sciences companies in Europe and Japan targeting chronic health conditions, welcomes Philippe De Backer as part of its management team as a Senior Partner.

Philippe brings extensive experience across different domains and valuable versatility to Newton Biocapital. With his background spanning science, investment, and value creation through partnerships, combined with an extensive European and international network within and outside life sciences, Philippe will be working closely alongside CEO Alain Parthoens to support the growth of Biotech and MedTech portfolio companies and to expand the current and future funds.

“I have known Philippe De Backer since the beginning of his career, and I am pleased to work together again. He has the right mixture of experience and expertise in science and business, emotional intelligence, entrepreneurship, and network to grow our business further.” says Alain Parthoens, CEO & Founder of Newton Biocapital.

Philippe obtained a PhD in Molecular Biology from VIB/Ghent University and an MBA from Solvay Business School, after which he joined an early-stage life sciences VC, where he met both Alain and Jean-Claude Deschamps, who today is Chairman Emeritus and Advisor to the Board of NBC. He became a member of the European Parliament in 2011, focussing on fund regulation and long-term investment, SME policy and industrial policy. In 2016, he became state secretary and later minister in the Belgian Federal Government. In March 2020, he was asked by prime minister Sophie Wilmes to lead the Federal Taskforce fighting the COVID pandemic in Belgium, procuring medical material and setting up testing capacity. After this successful crisis-management, he announced his return to life sciences and investing.

“I am excited to join Newton Biocapital with its extensive international network across Europe and Japan, its talented and experienced team, and to reunite with Alain Parthoens and Jean-Claude Deschamps for a renewed collaboration to foster life science innovation.”, says Philippe De Backer.

Philippe will strengthen the NBC team and organisation with his expertise in deal-sourcing and structuring early-stage companies, contributing to Newton Biocapital’s hands-on approach as lead investor. In doing so, NBC will continue to build on its long-standing investor relationships, such as with the Federal Participation and Investment Company SFPIM and several other public as well as private shareholders, to continue supporting the local biotech ecosystem. Newton Biocapital currently counts 14 leading biotech companies across Europe and Japan in its portfolio and has been instrumental in establishing four spin-off companies, among them Epics Therapeutics and NeuVasQ Biotechnologies, from leading universities in Belgium.

“It is a great privilege for me to welcome Philippe De Backer as a member of the Newton Biocapital management team. He will bring a fresh insight into the field of science and business while capitalising on his rich business and political experience. This will be an invaluable asset for NBC. In addition, he will add his passion and past investment practice to further enrich NBC’s high aspirations for the future years to come. I, along with the whole NBC team wish him the very best with NBC!” says Ajit Shetty, Chairman of NBC I & II.

--- END ---

For more information, please contact:

Kaori Sano, Global Relationship Director
Mobile: +32 473 30 52 33

About Newton Biocapital:

Newton Biocapital (NBC) is a VC firm focused on early-stage Life Sciences companies targeting chronic health conditions.  NBC is among the 8 VC firms certified by AMED in Japan to boost the pharma ecosystem and the only one with offices in Japan/Europe.  NBC’s diversified team of experts and its presence in Japan/Europe enable NBC to identify and select the most promising companies based on the outstanding research ecosystem in these two regions.  NBC provides investment opportunities that can help patients and society, as well as foster growth of the Japanese/European biotech ecosystems.

NBC is a hands-on investor and leverages its expertise to help its portfolio companies focus on the right indication and clinical trial design, thereby helping them progress successfully through the challenging early drug development phases up to the proof of concept in patients.  NBC enables time- and cost-effective translation from science to proof of concept in patients that attracts potential acquirers and unlocks value – for patients, companies, and investors.

Partner with us to unlock life sciences innovation, grow the biotech sectors and make an impact both locally and internationally.

About AMED (EN) & VC Certification Info (JP):

Record changed: 2024-01-06


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Newton Biocapital (NBC) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News How Covid Effects the Brain 650x300px

» top